| Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial J Cummings, S Isaacson, R Mills, H Williams, K Chi-Burris, A Corbett, ... The Lancet 383 (9916), 533-540, 2014 | 731 | 2014 |
| Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ... JAMA neurology 70 (10), 1277-1287, 2013 | 420 | 2013 |
| The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension CH Gibbons, P Schmidt, I Biaggioni, C Frazier-Mills, R Freeman, ... Journal of neurology 264, 1567-1582, 2017 | 416 | 2017 |
| The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ... Annals of clinical and translational neurology 5 (12), 1460-1477, 2018 | 375 | 2018 |
| Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti–α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial J Jankovic, I Goodman, B Safirstein, TK Marmon, DB Schenk, M Koller, ... JAMA neurology 75 (10), 1206-1214, 2018 | 266 | 2018 |
| Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial MA Schwarzschild, A Ascherio, MF Beal, ME Cudkowicz, GC Curhan, ... JAMA neurology 71 (2), 141-150, 2014 | 187 | 2014 |
| Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease–Clinical practice recommendations C Trenkwalder, KR Chaudhuri, PJG Ruiz, P LeWitt, R Katzenschlager, ... Parkinsonism & related disorders 21 (9), 1023-1030, 2015 | 172 | 2015 |
| ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial R Pahwa, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, ... JAMA neurology 74 (8), 941-949, 2017 | 169 | 2017 |
| Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) R Pahwa, CM Tanner, RA Hauser, K Sethi, S Isaacson, D Truong, ... Movement Disorders 30 (6), 788-795, 2015 | 162 | 2015 |
| Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) W Oertel, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, ... Movement Disorders 32 (12), 1701-1709, 2017 | 157 | 2017 |
| Droxidopa for the S hort‐T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B) RA Hauser, S Isaacson, JP Lisk, LA Hewitt, G Rowse Movement Disorders 30 (5), 646-654, 2015 | 152 | 2015 |
| Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study JE Tobin, JC Latourelle, MF Lew, C Klein, O Suchowersky, HA Shill, ... Neurology 71 (1), 28-34, 2008 | 148 | 2008 |
| Increased melanoma risk in Parkinson disease: a prospective clinicopathological study JM Bertoni, JP Arlette, HH Fernandez, C Fitzer-Attas, K Frei, MN Hassan, ... Archives of Neurology 67 (3), 347-352, 2010 | 131 | 2010 |
| A phase 2A trial of the novel mGluR5‐negative allosteric modulator dipraglurant for levodopa‐induced dyskinesia in Parkinson's disease F Tison, C Keywood, M Wakefield, F Durif, JC Corvol, K Eggert, M Lew, ... Movement Disorders 31 (9), 1373-1380, 2016 | 130 | 2016 |
| Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial AL Boxer, I Qureshi, M Ahlijanian, M Grundman, LI Golbe, I Litvan, ... The Lancet Neurology 18 (6), 549-558, 2019 | 123 | 2019 |
| Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo … PA LeWitt, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, ... The Lancet Neurology 18 (2), 145-154, 2019 | 119 | 2019 |
| The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study JC Latourelle, M Sun, MF Lew, O Suchowersky, C Klein, LI Golbe, ... BMC medicine 6, 1-7, 2008 | 119 | 2008 |
| Heightened expression of tumor necrosis factor alpha, interleukin 1 alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in mice. R Kordek, VR Nerurkar, PP Liberski, S Isaacson, R Yanagihara, ... Proceedings of the National Academy of Sciences 93 (18), 9754-9758, 1996 | 111 | 1996 |
| Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study CW Olanow, SA Factor, AJ Espay, RA Hauser, HA Shill, S Isaacson, ... The Lancet Neurology 19 (2), 135-144, 2020 | 107 | 2020 |
| Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross … T Simuni, L Uribe, HR Cho, C Caspell-Garcia, CS Coffey, A Siderowf, ... The Lancet Neurology 19 (1), 71-80, 2020 | 106 | 2020 |
Rajesh PahwaProfessor of Neurology, University of Kansas Medical Center Bestätigte E-Mail-Adresse bei kumc.edu
